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Background
Transfusion-dependency affects the natural history of myelodysplastic syndromes. Secondary
iron overload may concur to this effect. The relative impact of these factors on the outcome of
patients with myelodysplastic syndrome receiving allogeneic stem-cell transplantation remains
to be clarified. 
Design and Methods
We retrospectively evaluated the prognostic effect of transfusion history and iron overload on
the post-transplantation outcome of 357 patients with myelodysplastic syndrome reported to
the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) registry between 1997 and 2007. 
Results
Transfusion-dependency was independently associated with reduced overall survival (hazard
ratio=1.48, P=0.017) and increased non-relapse mortality (hazard ratio=1.68, P=0.024). The
impact of transfusion-dependency was noted only in patients receiving myeloablative condition-
ing (overall survival: hazard ratio=1.76, P=0.003; non-relapse mortality: hazard ratio=1.70,
P=0.02). There was an inverse relationship between transfusion burden and overall survival after
transplantation (P=0.022); the outcome was significantly worse in subjects receiving more than
20 red cell units. In multivariate analysis, transfusion-dependency was found to be a risk factor
for acute graft-versus-host disease (P=0.04). Among transfusion-dependent patients undergoing
myeloablative allogeneic stem cell transplantation, pre-transplantation serum ferritin level had a
significant effect on overall survival (P=0.01) and non-relapse mortality (P=0.03). This effect was
maintained after adjusting for transfusion burden and duration, suggesting that the negative
effect of transfusion history on outcome might be determined at least in part by iron overload.
Conclusions
Pre-transplantation transfusion history and serum ferritin have significant prognostic value in
patients with myelodysplastic syndrome undergoing myeloablative allogeneic stem cell trans-
plantation, inducing a significant increase of non-relapse mortality. These results indicate that
transfusion history should be considered in transplantation decision-making in patients with
myelodysplastic syndrome. 
Key words: transfusion-dependency, myelodysplastic syndromes, secondary iron
overload.
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Introduction 
Myelodysplastic syndromes (MDS) are a heteroge-
neous group of disorders characterized by peripheral
cytopenia and an increased risk of evolution into acute
myeloid leukemia (AML).1-3 The natural history of these
syndromes, which range from indolent conditions to
forms that rapidly progress to leukemia, complicates ther-
apeutic choices and timing of interventions.4
The only curative treatment for patients with MDS is
allogeneic stem cell transplantation (SCT).5-8 However,
given the considerable morbidity and mortality associat-
ed with this approach,9-11 candidate patients must be care-
fully selected.12,13 
All patients with MDS are likely to receive red blood
cell transfusions at some point during their disease.2 As a
consequence, many subjects with low-risk disease at
diagnosis have a long history of transfusion if they even-
tually undergo transplantation. The onset of transfusion
requirement has been found to affect the outcome of
MDS patients and is now considered an independent
indicator of disease severity.2,4,14 We observed, in addition,
that transfusion-dependent patients may have a reduced
survival after transplantation, and that the WHO classifi-
cation-based Prognostic Scoring System (WPSS),14 which
includes transfusion as a prognostic variable, improves
post-transplantation outcome stratification in MDS.15
Iron-related tissue damage is an important adverse
prognostic factor in transfusion-dependent patients with
thalassemia undergoing allogeneic SCT.16,17 Hepatic iron
accumulation, assessed by magnetic resonance imaging,
was recently found in MDS patients who had received 20
or more red cell units.18 Moreover, Armand et al. found
that a high pre-transplantation level of serum ferritin is
associated with poor outcome after transplantation.19 
In this study we retrospectively evaluated the prognos-
tic significance of pre-transplantation transfusion history
and secondary iron overload in a cohort of MDS patients
who underwent allogeneic SCT between 1997 and 2007. 
Design and Methods
Patients’ characteristics and transplant procedures
We studied 357 patients undergoing allogeneic SCT for pri-
mary MDS between 1997 and 2007 whose data were reported
to the GITMO registry. The procedures followed were in accor-
dance with the ethical standards of the Institutional Committee
on Human Experimentation and GITMO, as well as with the
Declaration of Helsinki. All clinical variables were analyzed at
the time of transplantation in patients undergoing upfront allo-
geneic SCT and at the time of remission-induction chemothera-
py in those receiving treatment before transplantation. 
One hundred and ninety-five patients were male and 162
were female. The median age was 49 years (range, 18-72 years).
Two hundred and forty-four patients were classified as having
MDS according to the WHO criteria,20 while 113 subjects, previ-
ously classified as having refractory anemia with excess blasts in
transformation according to the French-American-British crite-
ria, were considered to have AML secondary to MDS.
Cytogenetic data were available for 211 of the 244 patients with
MDS according to the WHO criteria (86%), and the
International Prognostic Scoring System21 and WPSS14 scores
were assessed in these patients. Data on extra-hematologic co-
morbidities, evaluated using the hematopoietic cell transplanta-
tion-specific co-morbidity index (HCT- CI),9 were obtained for
287 patients (80%). 
Transfusion history was defined in terms of transfusion
dependency, burden and duration. Transfusion-dependency was
defined, according to the WPSS criteria,14 as requiring at least
one red blood cell transfusion every 8 weeks over a period of 4
months before intensive treatment. Data were available for 325
patients (91%). The total number of packed red blood cell
(PRBC) units received before intensive treatment was recorded
for 203 patients. Serum ferritin levels were assessed before
intensive treatment (median time, 1.9 months; range, 0-5.9
months) in 228 patients (64%). In 157 patients data regarding
serum albumin, serum iron and transferrin levels were also col-
lected at the same time as serum ferritin was assessed (Table 1).
Seventeen patients received chelation therapy before transplan-
tation and were excluded from the analyses.
Allogeneic SCT was performed at a median of 9 months
(range, 1-189) after the diagnosis of MDS. The donors were
HLA-matched siblings in 229 cases (64%) and unrelated donors
in the other 128 cases (36%). Criteria for the selection of HLA-
matched unrelated donors before 2002 included low-resolution
typing for HLA class I (A, B) and high-resolution typing for HLA-
DRB1, whereas since 2002 the criteria included high-resolution
typing for both HLA class I (A, B, C) and class II alleles
(DRB1/3/4/5, DQA1, DPB1). The source of hematopoietic stem
cells was peripheral blood in 221 patients (62%) and bone mar-
row in 136 (38%). One hundred and fifty-two patients (43%)
received remission-induction chemotherapy prior to their trans-
plant. The conditioning regimen was myeloablative in 217
patients (61%) and of reduced-intensity in 140 patients (39%).
The most frequent conditioning regimens included total body
irradiation and cyclophosphamide (20% of cases), total body
irradiation and fludarabine (8%), busulphan and cyclophos-
phamide (28%), thiotepa and cyclophosphamide (26%), and
thiotepa and fludarabine (11%). For most patients, graft-versus-
host disease (GVHD) prophylaxis was a combination of
cyclosporine and methotrexate (Table 1).
End-points and statistical analysis
Numerical variables are summarized by their medians and
ranges, categorical variables by counts and relative frequencies.
The primary end-points were overall survival (OS), non-relapse
mortality (NRM) and probability of relapse. OS was defined as
the time between transplantation and death (from any cause) or
last follow-up (for censored observations). When estimating
NRM, any death in the absence of disease relapse was consid-
ered an event. The probability of relapse was estimated consid-
ering treatment as a failure at the time of hematologic relapse
according to standardized criteria.22 Acute GVHD and chronic
GVHD were also investigated. The cumulative probabilities of
OS, NRM and relapse were estimated using the Kaplan-Meier
product limit method. Comparisons between Kaplan-Meier
curves were carried out with the Gehan Wilcoxon test. The
probabilities of relapse and NRM were analyzed as competing
risks.23 Univariate and multivariate survival analyses were per-
formed using Cox proportional hazards regression to identify
the most significant independent prognostic factors. To decide
which parameterization of the covariates (categorical, with indi-
cator variables, versus continuous, with a single parameter) was
preferable, we carried out likelihood ratio tests, none of which
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was statistically significant. We, therefore, decided to treat all
covariates as continuous variables, for simplicity in the presen-
tation of the results. The risk factors associated with the occur-
rence of acute and chronic GVHD were investigated using mul-
tivariate logistic regression models. Analyses were performed
using Statistica 7.0 (Statsoft, Tulsa, OK, USA) and Stata 9
(StataCorp, College Station, TX, USA) software.
Results
Post-transplantation outcome according 
to transfusion-dependency
In the whole cohort, 5-year OS was 39%, the 5-year
probability of relapse was 42% and NRM was 41%. The
day-100 cumulative incidences of grade I and of grade II to
E.P. Alessandrino et al.
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Table 1. Clinical characteristics and transplant-related features of patients classified according to the WHO criteria at the time of allogeneic SCT
or remission-induction chemotherapy. 
Clinical variable All patients Transfusion-independent Transfusion-dependent P*
Number of patients 357 102 223
Median age 49 (18-72) 48 (18-65) 49 (21-72) ns
Sex (male/female) 195/162 58/44 121/102 ns
WHO classification
RA/RARS/MDSdel5q31 23 (7%) 6 (6%) 15 (7%)
RCMD/RS 61 (17%) 16 (16%) 41 (18%)
RAEB-1 53 (15%) 19 (19%) 34 (15%)
RAEB-2 107 (30%) 36 (35%) 63 (28%) ns
AML from MDS 113 (31%) 25 (24%) 70 (31%)
White blood cells (×109/L) 2.8 (0.1-26.7) 2.8 (0.5-26.7) 2.9 (0.1-7.3)
Absolute neutrophil count (×109/L) 1.22 (0.01-18.5) 1.36 (0.06-18.5) 1.16 (0.01-5.9) ns
Hemoglobin (g/dL) 8.9 (7.1-11.2) 9.75 (7.9-11.2) 8.6 (7.1-9.6) ns
Platelets (×109/L) 50 (3-686) 64 (29-577) 46 (3-686) ns
Cytogenetics 211/244 (86%) 72/77 139/153 ns
Transfusion-dependency 223/328 (68%)
Duration of transfusion-dependency (months) − 8 (2-183)
Transfusion burden − 20 (5-151)
Serum ferritin (ng/mL) 980 (7-11800) 426 (7-2260) 1326 (685-11800)
HCT-CI risk 287/357 (80%) 86/102 201/223 <0.001
Low 170 (59%) 61 (71%) 109 (54%)
Intermediate 78 (27%) 15 (17%) 63 (31%) 0.04
High 39 (14) 10 (12%) 29 (14%)
International prognostic scoring system risk: 211/244 (86%) 72/77 139/153
Low 5 (2%) 4 (6%) 1 (1%)
Intermediate-1 84 (40%) 22 (31%) 62 (45%) ns
Intermediate-2 95 (45%) 38 (53%) 57 (41%)
High 27 (13%) 8 (11%) 19 (14%)
WPSS risk: 211/244 (86%) 72/77 139/153
Very-low 3 (1%) 3 (4%) −
Low 24 (11%) 11 (15%) 13 (9%) 0.036
Intermediate 37 (18%) 8 (11%) 29 (21%)
High 119 (56%) 43 (60%) 76 (55%)
Very high 28 (14%) 7 (10%) 21 (15%)
Time from diagnosis to allogeneic SCT 9 (1-189) 7.6 (1-24) 10.7 (1-189) 0.004
Type of donor
Sibling 229 (64%) 76 (75%) 144 (65) ns
Matched unrelated 128 (36%) 26 (25%) 79 (35)
Source of hematopoietic stem cells
Peripheral blood 221 (62%) 58 (57%) 150 (67%) ns
Bone marrow 136 (38%) 44 (43%) 73 (33%)
Remission-induction chemotherapy 152 (43%) 45 (44%) 95(42%) ns
Complete remission 89 (58%) 28 (62%) 53 (56%) ns
Conditioning
Standard conditioning regimen 217 (61%) 73 (72%) 135 (61%) 0.024
Reduced-intensity conditioning 141 (39%) 30 (29%) 88 (39%)
*Comparison between transfusion-independent and transfusion-dependent patients.RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts,RCMD: refractory
cytopenia with multilineage dysplasia; RS: ringed sideroblasts; RAEB: refractory anemia with excess blasts.
IV acute GVHD were 23% and 39%, respectively. The 5-
year cumulative incidences of overall and extensive chron-
ic GVHD were 64% and 34%, respectively.
A regular transfusion need before transplantation was
reported in 223 (68%) of 328 evaluable subjects. The
median number of PRBC units received was 20 (range, 5-
151). Considering that each unit of blood contains approx-
imately 200-250 mg of iron, the median intake of iron due
to transfusions was 4 g (range, 1- 30 g). The median dura-
tion of transfusion-dependency was 8 months (range, 2-
183 months). There was no significant difference in the
proportion of transfusion-dependent patients among the
WHO categories (P=0.31). The time between diagnosis
and transplantation was longer among transfusion-
dependent patients than among patients who did not
receive transfusion therapy, (10.7 versus 7.6 months;
P=0.004). The transfusion-dependent patients had a high-
er HCT-CI score (P=0.04) and an increased percentage of
reduced-intensity conditioning (RIC) (39% versus 28%;
P=0.024) (Table 1). An increased occurrence of acute
GVHD was noted in transfusion-dependent patients (67%
versus 57%; P=0.03), while no significant difference was
seen in chronic GVHD. 
In univariate analysis, transfusion-dependency signifi-
cantly affected OS (HR 1.68; P<0.001), NRM (HR 1.72;
P=0.001), and probability of relapse (HR 1.61; P=0.011).
We performed a multivariate Cox survival analysis with
the following covariates: WHO category, cytogenetic risk
(scored according to the International Prognostic Scoring
System), transfusion-dependency, absolute neutrophil
count, hemoglobin and platelet levels, presence of extra-
hematologic co-morbidities (according to the HCT-CI),
age of recipient, time between diagnosis and transplanta-
tion, year of transplantation (1997-2002 versus 2003-2007),
disease stage at transplantation (complete remission or
marrow blasts <5% versus not complete remission or
blasts ≥5%), remission-induction chemotherapy (received
versus not received), source of hematopoietic stem cells
(peripheral blood versus bone marrow), type of donor
(HLA-identical sibling versus matched unrelated donor)
and type of conditioning (myeloablative conditioning reg-
imen versus RIC).
Recipient age, WHO category, disease stage at trans-
plantation, HCT-CI and type of donor had significant
effects on OS. WHO category with excess blasts, unfavor-
able cytogenetics, active/progressive disease at transplan-
tation, RIC, and the use of an HLA-identical sibling donor
were associated with a higher probability of relapse.
Recipient age, transplantation prior to 2003, use of mye-
loablative conditioning, HLA-matched unrelated donor
and high HCT-CI score were significant risk factors for
NRM (Table 2).
To clarify the prognostic effect of disease status at trans-
plantation we considered patients stratified according to
WHO category and type of conditioning regimen. In
patients with AML from MDS, there were significant
advantages of undergoing transplantation in complete
remission in both the groups given standard conditioning
and RIC (OS: HR=0.48, P=0.02 and HR=0.37, P=0.039,
respectively; probability of relapse: HR=0.41, P=0.017 and
HR=0.19, P=0.009, respectively). Considering patients
affected with refractory anemia with excess blasts-1 and -
2, a borderline effect on the probability of relapse was
noted only among patients receiving RIC (HR=0.44,
P=0.06).
Transfusion-dependency had a significant effect on both
OS (HR=1.48, P=0.017) and NRM (HR=1.68, P=0.024),
whereas no significant effect was found for the probabili-
ty of relapse (HR=1.21, P=0.46) (Table 2, Figure 1A). The
prognostic effect of transfusion-dependency was main-
tained when the analysis was focused on the 244 patients
with a diagnosis of MDS according to the WHO criteria
(OS: HR=1.64, P=0.016; NRM: HR=1.76, P=0.042).
In order to verify whether the introduction of transfu-
sion-dependency may improve the prognostic stratifica-
tion of MDS patients undergoing allogeneic SCT, we fit-
ted two separate multivariate Cox analyses including the
same covariates as detailed above with and without trans-
fusion-dependency, and compared them with the likeli-
hood ratio test. This resulted in a significant P value
(P=0.004), confirming the importance of accounting for
transfusions in the prognostic model.
We then carried out separate multivariate analyses to
investigate the prognostic effect of transfusion-dependen-
cy in selected subgroups of patients. When stratifying
according to type of conditioning, transfusion-dependen-
cy retained a significant effect in patients receiving mye-
Impact of pre-transplantation transfusion in MDS
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Table 2. Prognostic factors for post-transplantation outcome in the whole study
population (multivariate analysis).
Clinical variables OS Probability NRM
of relapse
HR P HR P HR P
Recipient sex 0.91 0.52 1.07 0.79 0.78 0.26
Recipient age * 1.024 0.001 1.005 0.12 1.18 0.04
Year of transplantation 0.71 0.09 1.01 0.68 0.62 0.03
(1997-2002 vs. 2003-2007)
Time from diagnosis to SCT* 0.99 0.89 0.91 0.74 0.98 0.84
WHO categories* 1.23 0.001 1.47 <0.001 1.09 0.45
Cytogenetic risk* 1.18 0.11 1.50 0.010 1.04 0.38
Transfusion-dependency* 1.48 0.017 1.21 0.46 1.68 0.024
Absolute neutrophil count* 1.008 0.41 0.97 0.45 0.99 0.88
Hemoglobin level* 0.98 0.11 0.95 0.48 0.88 0.10
Platelet level* 0.99 0.98 1.000 0.99 1.000 0.97
HCT-CI 
(low vs. intermediate vs.high) 1.20 0.014 0.77 0.12 1.37 <0.001
Disease stage at transplant 
(complete remission vs. 1.38 0.033 1.52 0.04 0.71 0.12
active/progressive disease)
Conditioning regimen, 0.87 0.28 1.85 0.022 0.57 0.037
(standard conditioning vs RIC)
Source of stem cells 1.15 0.38 1.20 0.52 1.31 0.13
(peripheral blood vs.bone marrow)
Type of donor 1.43 0.022 0.45 0.018 2.01 <0.001
(HLA-identical sibling vs.
matched unrelated donor)
*Clinical and demographic variables were evaluated at the time of transplantation in patients
undergoing upfront allogeneic SCT, and before remission-induction chemotherapy in patients
receiving treatment before transplantation.
loablative conditioning (OS: HR=1.76, P=0.003; NRM:
HR=1.70, P=0.02; probability of relapse: HR=1.47, P=0.22,
Table 3, Figure 1B), whereas no significant effect was seen
in patients receiving RIC (OS: HR=0.84, P=0.60; NRM:
HR=0.67, P=0.28; probability of relapse: HR 0.81, P=0.63). 
When focusing on MDS patients without excess blasts,
transfusion-dependency significantly affected post-trans-
plantation OS (HR=3.01, P=0.014) and was associated
with increased NRM (HR=3.49, P=0.02). Among MDS
patients with excess blasts or MDS-AML, transfusion-
dependency retained a significant effect on both OS
(HR=1.50, P=0.012) and NRM (HR=1.69, P=0.031). 
Finally, we analyzed relapse and NRM as competing
risks in these subgroups of patients. Considering patients
receiving myeloablative conditioning, the cumulative inci-
dences of relapse and NRM were 23% and 33%, respec-
tively, in transfusion-independent patients and 24% and
45%, respectively, in transfusion-dependent patients.
Among the patients receiving RIC, the cumulative inci-
dences of relapse and NRM were 64% and 21%, respec-
tively, in transfusion-independent patients and 52% and
22%, respectively, in transfusion-dependent patients.  
Focusing on patients with excess blasts or MDS-AML,
the cumulative incidences of relapse and NRM were 35%
and 33%, respectively, in transfusion-independent
patients and 34% and 43%, respectively, in transfusion-
dependent patients. In patients without excess blasts, the
cumulative incidences of relapse and NRM were 10% and
26%, respectively, in transfusion-independent patients
and 17% and 33%, respectively, in transfusion-dependent
patients.
Post-transplantation outcome according 
to transfusion burden
We focused on 135 transfusion-dependent subjects
receiving myeloablative conditioning, with the aim of
investigating the prognostic effect of the transfusion bur-
den in these patients. We first performed a multivariate
analysis including the number of received PRBC units as a
continuous variable, and adjusting for duration of transfu-
sion need. WHO category, cytogenetics, absolute neu-
trophil count, hemoglobin and platelet levels, age of recip-
ient, disease stage at transplantation, source of hemato-
poietic stem cells and type of donor were also included as
covariates. The number of PRCB units received showed a
significant effect on OS (HR=1.029, P=0.022) and NRM
(HR=1.034, P=0.021). 
These results were confirmed when transfusion-
dependent patients were grouped into three categories
according to whether they received 20 or fewer PRBC
units (64 patients, 47%), 21-40 PRBC units (45 patients,
33%), or more than 40 PRBC units (26 patients, 19%)
prior to transplantation (OS: HR=1.34, P=0.04; NRM:
HR=1.47 P=0.021) (Figure 2). 
With respect to transfusion-independent patients, no
significant difference was found between patients receiv-
ing 20 or fewer PRBC units before transplantation and
transfusion-independent patients (P=0.08 and P=0.24 for
OS and NRM, respectively), while post-transplantation
outcome was significantly worse in patients receiving 21-
40 PRBC units (P=0.002 and P=0.015 for OS and NRM,
respectively) and more than 40 PRBC units (P<0.001 and
E.P. Alessandrino et al.
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Figure 1. Post-transplantation outcome according to the presence of
transfusion-dependency. Probability of OS and NRM after allogeneic
hematopoietic SCT in the whole MDS population (A, B, respectively)
and in patients receiving myeloablative conditioning (C, D, respec-
tively). The curves were estimated from multivariable Cox regression
analysis adjusted for the patients’ age and sex, WHO category, cyto-
genetics, disease status at transplant, presence of comorbidities,
source of stem cells, type of donor and type of conditioning. 
P<0.001 for OS and NRM, respectively). 
An analysis of the 96 patients with a diagnosis of MDS
according to the WHO criteria showed that transfusion
burden has a significant effect on NRM (HR=1.56,
P=0.023) and a borderline effect on OS (HR=1.39,
P=0.063).
Finally, we carried out multivariate logistic regression
analyses for the presence of acute and chronic GVHD
using recipient age, presence of transfusion-dependency,
source of hematopoietic stem cell and type of donor as
covariates. Transfusion-dependency was found to be an
independent risk factor for developing acute GVHD
grades II to IV (P=0.04), while no significant effect on the
occurrence of chronic GVHD was noted.
Post-transplantation outcome according to serum
ferritin level
We evaluated the impact of secondary iron overload, as
assessed by serum ferritin levels, on the outcome of trans-
fusion-dependent MDS patients undergoing myeloabla-
tive allogeneic SCT. Pre-transplantation serum ferritin val-
ues were available for 129 out of 135 patients (median
value, 1270 ng/mL; range, 547-11800 ng/mL). A significant
correlation was seen between the number of PRBC units
received before transplantation and serum ferritin level
(r=0.46, P<0.001). 
In order to verify whether increased ferritin level was an
expression of iron overload in transfusion-dependent
patients, we analyzed the percentage of transferrin satura-
tion: the median value was 86% (range, 58-100%).
Transfusion-dependent patients were grouped on the
basis of serum ferritin concentration as follows: serum fer-
ritin less than 1000 ng/mL (47 patients, 36%), 1000-1999
ng/mL (55 patients, 43%), 2000-3000 ng/mL (17 patients,
13%) and more than 3000 ng/mL (10 patients, 8%). Pre-
transplantation ferritin level showed a significant effect on
OS (HR=1.40, P=0.01) and NRM (HR=1.42 P=0.03) in a
multivariate analysis including WHO category, cytogenet-
ics, absolute neutrophil count, hemoglobin and platelet
levels, age of recipient, disease stage at transplantation,
source of hematopoietic stem cells and type of donor as
co-variates (Figure 3). No significant effect on probability
of relapse was found.
After adding transfusion burden (number of PRBC units)
and transfusion duration to the model, the effect of serum
ferritin was maintained on both OS and NRM (HR=1.47
P=0.038 and HR=1.54 P=0.04, respectively). A trend
towards transfusion burden having a significant effect on
post-transplantation outcome was also detected (OS:
HR=1.34 P=0.10; NRM: HR=1.43, P=0.09). Limiting the
analysis to transfusion-dependent patients with a diagno-
sis of MDS according to the WHO criteria, serum ferritin
level showed a negative effect on NRM (HR=1.44, P=0.04)
and a borderline effect on OS (HR=1.39, P=0.07).
In order to account for the possible role of ferritin as an
acute-phase reactant, we included pre-transplantation
serum albumin in the model, and we found that the
impact of ferritin on outcome was unchanged (data not
shown).
Finally, applying the same multivariate analysis to trans-
fusion-dependent patients receiving RIC, no significant
effect of pre-transplantation serum ferritin on OS
(HR=1.03, P=0.61) or NRM (HR=1.11 P=0.28) was
observed.
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Table 3. Prognostic factors for post-transplantation outcome in 217 MDS patients receiving myeloablative conditioning (multivariate analysis).
Clinical variables OS Probability of relapse NRM
HR P HR P HR P
Recipient sex 0.74 0.09 1.38 0.42 0.64 0.048
Recipient age* 1.026 0.003 1.01 0.15 1.022 0.031
Time from diagnosis to SCT* 0.99 0.97 0.98 0.23 1.002 0.35
WHO categories* 1.2 0.017 1.52 .003 1.05 0.57
Cytogenetic risk* 1.88 0.058 1.77 .007 1.01 0.93
Transfusion-dependency* 1.76 0.003 1.47 0.22 1.69 0.023
Absolute neutrophil count* 1.03 0.19 1.035 0.57 1.031 0.12
Hemoglobin level* 0.93 0.21 0.94 0.62 0.90 0.11
Platelet level* 0.99 0.98 1.000 0.93 1.000 0.82
HCT-CI 
(low vs. intermediate vs. high) 1.28 0.03 0.96 0.87 1.32 0.019
Disease stage at transplant 
(complete remission vs. active/progressive disease) 1.21 0.23 1.27 0.10 1.12 0.63
Source of stem cells
(peripheral blood vs.bone marrow) 1.23 0.28 0.88 0.73 1.32 0.24
Type of donor
(HLA-identical sibling vs. matched unrelated donor) 1.58 0.014 0.45 0.06 2.11 <0.001
*Clinical and demographic variables were evaluated at the time of transplant in patients undergoing upfront allogeneic SCT,and before remission-induction chemotherapy in
patients receiving treatment before transplantation.
Discussion
We previously showed that transfusion-dependent
MDS patients may have a reduced survival after transplan-
tation, and that the WPSS score, which includes transfu-
sion as a prognostic variable, is able to stratify post-trans-
plantation outcome in patients with MDS.15 The present
study had a wider scope. The analysis was focused on a
more recent and restricted period, in which transplant pro-
cedures have become more homogeneous and data regis-
tration more complete and accurate. Moreover, the clinical
effects of additional parameters such as pre-transplanta-
tion transfusion burden and duration and serum ferritin
level were assessed.
We clarified that the negative impact of transfusion-
dependency is associated with an increased risk of NRM,
while no significant effect was seen on the probability of
relapse. The effect of transfusion-dependency was
restricted to MDS patients who received a myeloablative
conditioning regimen and are, therefore, at higher risk of
developing transplant-related toxicity; no significant effect
was noted in patients receiving RIC. An inverse relation-
ship was seen between transfusion burden and probabili-
ty of surviving after transplantation: post-transplantation
outcome was comparable between patients receiving 20
or fewer PRBC units and transfusion-independent
patients, but was significantly worse in subjects with a
long history of transfusion-dependency. We also found
that the negative effect of transfusion history on post-
transplantation outcome might be related at least in part
to secondary iron overload. 
In MDS, the presence of transfusion-dependency has
already been shown to have a negative prognostic value
due to the concomitant effect of more severe anemia,
more aggressive disease and secondary iron overload.1,2,14
Recently, an elevated pre-transplantation serum ferritin
level was found to be associated with reduced survival in
patients with MDS.19,24 Nevertheless, these studies were
potentially biased by the fact that they did not take into
account transfusion history before transplantation. It is
very important to clarify whether high ferritin levels at the
time of transplantation were due to transfusions or inflam-
mation: in fact, these two clinical conditions are quite dif-
ferent in terms of biological characteristics and, more
E.P. Alessandrino et al.
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Figure 2. Post-transplantation outcome of MDS patients receiving
standard conditioning according to transfusion burden: probability
of overall survival, (A) and non-relapse mortality, (B). Patients were
categorized as receiving 20 or fewer, 20-40, or more than 40
PRBC units. The curves were estimated from multivariable Cox
regression analysis adjusted for patients’ age and sex, WHO cate-
gory, cytogenetics, disease status at transplant, presence of
comorbidities, duration of transfusion dependency, source of stem
cells and type of donor.
Figure 3. Post-transplantation outcome of transfusion-dependent
patients receiving standard conditioning according to serum fer-
ritin level: probability of overall survival, (A) and non-relapse mor-
tality, (B) Patients were categorized as follows: serum ferrtin
<1000 ng/mL, 1000-1999 ng/mL, 2000-3000 ng/mL and >3000
mg/mL. The curves were estimated from multivariable Cox
regression analysis adjusted for patients’ age and sex, WHO cate-
gory, cytogenetics, disease status at transplant, presence of
comorbidities, source of stem cells and type of donor.
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importantly, iron metabolism.25
The prognostic effect of transfusion-dependency, the
relationship between transfusion burden and transplant-
related mortality but not relapse rate, the selective effect
in patients receiving myeloablative conditioning, the esca-
lating effect of transfusion burden, the relationship
between serum ferritin and transplantation outcome, the
fact that there is no difference between non-transfused
and lightly transfused patients, all consistently indicate a
direct effect of secondary iron overload on post-transplan-
tation outcome. 
Our results also suggest that the presence of pre-trans-
plantation transfusion-dependency might be a risk factor
for acute GVHD. It is possible to speculate that the pres-
ence of parenchymal iron overload, through free iron rad-
ical-mediated injury, may increase the susceptibility of
organs (in particular the liver) to GVHD. 
Data on the role of iron in organ damage in MDS are
limited.26 Serum ferritin is the most commonly used indi-
rect estimate of iron overload,27,28 and a direct correlation
between serum ferritin and the number of transfusions
received has been observed.2 On average, each PRBC unit
adds about 200-250 mg of iron to the total iron pool in the
body, and iron overload can occur after about 20 transfu-
sions.28 It was recently shown that all MDS patients who
had received 20 or more red cell units has iron accumula-
tion in the liver, as detected by magnetic resonance imag-
ing,18 and serum ferritin was found to have a significant
impact on survival of patients with refractory anemia.2,4
In this study we observed a significant effect of serum
ferritin in transfusion-dependent MDS patients who
underwent myeloablative allogeneic SCT. The effect was
maintained after adjusting for both transfusion burden
and duration. The negative effect of increased serum fer-
ritin levels was mainly an increased NRM, while no effect
on the probability of relapse was seen. Secondary iron
overload did not have an effect on patients receiving RIC,
who were less exposed to the risk of NRM with respect to
those receiving a standard conditioning regimen.
A single determination of serum ferritin level as a mark-
er of iron overload should be considered with some cau-
tion due to its concomitant role as acute-phase reactant.27,28
However, we found that the prognostic effect of serum
ferritin was unlikely to have depended substantially on
acute-phase issues. Moreover, when considering transfer-
rin saturation to define the site of iron accumulation25 we
observed very high values, suggesting the presence of
parenchymal iron loading in transfusion-dependent
patients.
There are potential sources of bias in our analysis, inher-
ent to the retrospective nature of a study based on a trans-
plantation registry. However, data about transfusion histo-
ry and pre-transplantation serum ferritin were available
for the great majority of the original population of
patients, and the analyses were adjusted for all known
potential confounding factors by adopting multivariate
techniques and/or performing stratified and subgroup
analyses. Therefore, in spite of the limitations, the find-
ings of this study might have relevant clinical implications.
Our results suggest that transfusion history should be
considered in MDS transplantation decision-making, as
also indicated by the significant impact of WPSS score on
post-transplantation outcome.15 For patients who are can-
didates for allogeneic SCT, it is very important to avoid
complications related to the presence of transfusion-
dependent anemia (such as secondary iron overload), and
this might be particularly relevant for younger patients,
who usually receive a myeloablative conditioning. A deci-
sion analysis from the International Bone Marrow
Transplant Registry demonstrated that life expectancy of
patients with low-risk MDS was longer when transplanta-
tion was delayed by some period.29 However, the addi-
tional risk of disease complications that might increase
transplant toxicity or preclude these patients from a later
transplantation are to be considered when implementing
delayed treatment strategies in clinical practice. 
On the other hand, patients with a long history of trans-
fusion and evidence of iron overload at the time of trans-
plantation might benefit for a reduced-intensity condition-
ing regimen, in order to reduce the probability of NRM. 
Finally, the results of the present study support the
rationale for direct evaluation of iron overload and iron-
mediated tissue damage in MDS patients who are candi-
dates for allogeneic SCT and for clarifying the possible
role of chelation therapy in reducing transfusion-related
complications in these patients.
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